Gliflozins and Atrial Fibrillation
Authors:
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial EnergeticsJACC, 2019
- Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME TrialCirculation, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term RegistryEuropean Heart Journal, 2018
- Inflammation – Cause or Consequence of Heart Failure or Both?Current Heart Failure Reports, 2017
- Heart Failure With Preserved Ejection Fraction and Atrial FibrillationJACC, 2016
- Atrial Fibrillation Begets Heart Failure and Vice VersaCirculation, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- The pathophysiology of heart failure with preserved ejection fractionNature Reviews Cardiology, 2014
- Heart Failure With Preserved Ejection FractionCirculation Research, 2014